Strategic Advisory for Leading Therapeutics Innovation Inc. (SALTI) has officially launched and is set to establish a new standard in life sciences consulting. The company was founded by Sherif Salti, a distinguished leader in digital transformation in the life sciences sector. SALTI is uniquely positioned to offer differentiated partnership, drawing from Salti’s extensive track record of successful transformations across the industry. The firm aims to capitalize on emerging opportunities and drive significant advancements in life sciences commercialization. SALTI integrates a team of experts in launch excellence, digital transformation, scientific and medical advisory, advanced analytics, and more, expanding on the vision of its founder to “Advance Medicine, Transform Lives.”
Ray Gomez, reflecting on his partnership with Sherif Salti over the years that shaped transformative strategies globally during his past collaborations as Vice President of Worldwide Omnichannel Capabilities at Bristol Myers Squibb, lauded his contributions: “Sherif Salti is an exceptional leader whose profound expertise and unwavering dedication have been pivotal in our transformation initiatives. His strategic acumen and meticulous attention to detail have been crucial in navigating complex challenges and delivering superior outcomes.”
The strategic importance of specialty markets cannot be overstated in an industry that is propelled by rapid innovation and intricate challenges. Oncology is the leading area of medicine costs globally, with a projected spend of $377 billion by 2027. This highlights the critical need for specialized expertise within life sciences organizations. At the same time, the rise of emerging biopharmaceutical companies marks a crucial trend in the industry. However, these agile and innovative entities often find themselves hindered by the bureaucratic inertia typical of larger, traditional strategic advisory partners. Such companies, which are vital for driving sector-wide innovation, require partners who mirror their agility and can adapt swiftly to changing market dynamics.
SALTI, with its focused and agile teams, is uniquely equipped to meet these needs. The approach of this new firm delivers clear and strategic insights without the burdensome overhead of conventional models. This fosters an environment where strategic planning can seamlessly transition into impactful execution.
Sherif Salti elaborates on the firm’s operational ethos: “Our aim is to enhance our clients’ ability to innovate autonomously. We provide the roadmap and tools, but our goal is to empower clients to lead their own advancements effectively. To that end, a forthcoming roadmap from SALTI includes the introduction of strategic capability ‘accelerators’—tools and frameworks designed to significantly enhance the efficiency and effectiveness of life sciences capabilities, particularly for new product launches.”
